STRS Ohio’s Anika Therapeutics ANIK Stock Holding History

STRS Ohio’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$281K	Buy	19,200 +3,600	+23%	+$53.4K	﹤0.01%	1431
2026 Q1	$226K	Hold	15,600	–	–	﹤0.01%	1446
2025 Q4	$150K	Buy	15,600 +1,700	+12%	+$16.3K	﹤0.01%	1660
2025 Q3	$131K	Buy	+13,900	New	+$133K	﹤0.01%	1742
2024 Q3	–	Sell	-4,000	Closed	-$101K	–	1967
2024 Q2	$101K	Buy	+4,000	New	+$104K	﹤0.01%	1696
2023 Q3	–	Sell	-21,400	Closed	-$555K	–	1936
2023 Q2	$555K	Buy	21,400 +600	+3%	+$16.1K	﹤0.01%	1225
2023 Q1	$597K	Buy	+20,800	New	+$619K	﹤0.01%	1187
2018 Q2	–	Sell	-5,400	Closed	-$268K	–	2116
2018 Q1	$268K	Buy	+5,400	New	+$305K	﹤0.01%	1450
2015 Q2	–	Sell	-19,800	Closed	-$706K	–	1859
2015 Q1	$815K	Sell	19,800 -1,000	-5%	-$40.4K	﹤0.01%	905
2014 Q4	$847K	Buy	20,800 +300	+1%	+$11.7K	﹤0.01%	886
2014 Q3	$752K	Buy	20,500 +2,600	+15%	+$112K	﹤0.01%	903
2014 Q2	$829K	Sell	17,900 -1,200	-6%	-$53.4K	﹤0.01%	898
2014 Q1	$785K	Sell	19,100 -3,400	-15%	-$126K	﹤0.01%	883
2013 Q4	$859K	Buy	22,500 +11,900	+112%	+$367K	﹤0.01%	849
2013 Q3	$254K	Buy	+10,600	New	+$238K	﹤0.01%	1422

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

STRS Ohio's ANIK Position: Q2 2026 in Review

STRS Ohio increased its Anika Therapeutics (ANIK) stake by 23% in Q2 2026, buying an estimated $53.4K and bringing the position to 19,200 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #1431.

STRS Ohio first reported a position in ANIK in Q3 2013 and has held it in 15 quarters since. The position peaked at $859K in Q4 2013. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

STRS Ohio held 19,200 shares of Anika Therapeutics worth $281K as of Q2 2026.
STRS Ohio bought 3,600 Anika Therapeutics shares in Q2 2026, an estimated $53.4K.
Anika Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1431 holding.
STRS Ohio first reported a position in Anika Therapeutics in Q3 2013 and has held it in 15 quarters since.
STRS Ohio's Anika Therapeutics position peaked at $859K in Q4 2013.
133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.